Empowering Myeloid Cells to Better Address Unmet Clinical Needs

To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.

  • (Reverse)Translational Science

    Clinical Experience   Basic Research

    Identification of patients' unmet needs, novel targets, pathways, and mechanisms.

  • Drug Discovery & Development

    Myeloid Engager

    Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.

  • Immunotherapy

    Clinical Benefit

    Boosting of anti-tumor immunity to fight against cancer.

Our Myeloid Engager Platform

Novel Mechanism of Action

Direct engagement of myeloid cells with target cells.

Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.

Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.

Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.

We have a global character of innateness
in our science & culture.

Latest News

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases

REDWOOD CITY, Calif. and SHENZHEN, China July 29, 2025

REDWOOD CITY, California and SHENZHEN, China – July 29, 2025 – LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop novel myeloid engager therapeutics against selected targets for the treatment of diseases with high unmet need.

Follow Us
  • Stay ln Touch

    General Inquiries

    info@ltztherapeutics.com

    Business Development

    vivian.tian@ltztherapeutics.com
  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057

@ 2025 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果,移动端请竖屏浏览